US 12,233,056 B2
Lysyl oxidase inhibitors for treating myeloid malignancies
Wolf-Karsten Hofmann, Mannheim (DE); Daniel Nowak, Mannheim (DE); Vladimir Ryabov, Mannheim (DE); Qingyu Xu, Mannheim (DE); and Eva Altrock, Vaihingen/Enz (DE)
Assigned to Syntara Limited, Frenchs Forest (AU)
Filed by Syntara Limited, Frenchs Forest (AU)
Filed on Apr. 5, 2023, as Appl. No. 18/131,183.
Claims priority of application No. 2022900904 (AU), filed on Apr. 6, 2022.
Prior Publication US 2023/0321075 A1, Oct. 12, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/47 (2006.01); A61K 31/706 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01)
CPC A61K 31/47 (2013.01) [A61K 31/706 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01)] 9 Claims
OG exemplary drawing
 
1. A method for the treatment of a myeloid malignancy in a subject, the method comprising administering to the subject a therapeutically effective amount of a lysyl oxidase (LOX) inhibitor, a lysyl oxidase-like (LOXL) inhibitor, or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the inhibitors or salts, wherein the LOX or LOXL inhibitor is

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, the method further comprising administering to the subject one or more additional therapeutic agents or a pharmaceutical composition comprising one or more of the additional agents, wherein the additional therapeutic agent is a hypomethylating agent or a pharmaceutically acceptable salt thereof.